CERE Investors Have Opportunity to Lead Cerevel Therapeutics Holdings, Inc. Securities Fraud Lawsuit

Provided By PR Newswire

Last update: May 10, 2025

NEW YORK, May 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds all persons or entities that: (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period"); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline.